Gilead SciencesNASDAQ: GILD

Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to market expansion and creating shareholder value. Gilead's diversified revenue streams from HIV, liver disease, COVID-19, and oncology products position the company for continued growth and success.

Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections.

Gilead (GILD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in women.

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm unveiled new data from a late-stage PURPOSE trial which showed its twice-yearly injectable HIV therapy lenacapavir is 100% effective in preventing HIV in women.   Notably, lenacapavir was shown to be superior to once-daily oral Truvada, which is one of several medications currently used to treat HIV and to prevent HIV infection, known as pre-exposure prophylaxis (PrEP).

Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.

Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.